• +49 89 206054 130
  • info@kloepfel-cf.com
KloepfelLogo_RGBKloepfelLogo_RGBKloepfelLogo_RGBKloepfelLogo_RGB
  • About us
    • Company
    • Our values
    • Team
    • Advisory board
    • Kloepfel Group
    • Cooperation partners
  • Services
    • M&A – Sell Side Advisory
    • M&A – Buy Side Advisory
    • Corporate Finance
    • Debt Advisory
    • IPO Advisory – Going public procedure
    • SPAC-Advisory
  • References
    • Transactions
    • Testimonials
  • News
    • Downloads
    • Expert knowledge
    • Press mirror
    • Press Releases
    • Research Report
  • Contact
English
✕

Kloepfel Corporate Finance exclusively advised WITTENSTEIN SE on the disposal of its med-tech business to medical device specialist Orthofix

on 10. February 2020
Categories
  • M&A - Sell Side Advisory
  • Date10. February 2020

Orthofix-WittensteinKloepfel Corporate Finance exclusively advised WITTENSTEIN SE on the disposal of its med-tech business to medical device specialist Orthofix.

Munich, February 2020 – Kloepfel Corporate Finance has acted as exclusive financial adviser to WITTENSTEIN SE (WITTENSTEIN) on the sale of its med-tech business to US based stock listed Orthofix Medical Inc. (Orthofix). The acquisition is anticipated to close by the end of the first quarter of 2020 subject to customary closing conditions.

Orthofix will take over the portfolio of medical devices – comprised of FITBONE® and FITSPINE® – from WITTENSTEIN subsidiary WITTENSTEIN intens GmbH. WITTENSTEIN believes that the development and marketing opportunities will be significantly improved as a result of transferring this innovative, human centered drive technology to Orthofix, a global leader in the field of medical devices.
WITTENSTEIN intens GmbH develops, manufactures and markets smart implants for use in orthopedics and traumatology in particular intramedullary limb lengthening as well as controllable mechatronic drive systems for med-tech applications.

“It is increasingly difficult for a classic engineering firm like WITTENSTEIN to take adequate account of the specific characteristics of the med-tech business”, said Dr. Bertram Hoffmann, CEO of WITTENSTEIN, when asked to comment on the sale. “We, the Supervisory Board and the owning Wittenstein family are united by a common conviction that an established, specialized company in the med-tech industry is much better positioned to continue developing and perfecting WITTENSTEIN’s medical technology successfully.

With the addition of the FITBONE system, Orthofix becomes the only orthopedic company that offers a comprehensive portfolio of both internal and external fixation solutions for limb reconstruction. The FITBONE system will augment Orthofix’s current deformity and limb reconstruction offerings that include the TL-HEX™ computer-assisted ring fixation system for external limb lengthening and the eight-Plate Guided Growth System™ for correcting angular growth deformities in pediatric patients.

„Kloepfel Corporate Finance has given us excellent advice in all relevant business, financial and process-tactical aspects of the sales process with great commitment and dedication. With the right negotiating skills and at the same time a high level of fairness, it was possible to achieve an outstanding result in such a complex and time-consuming transaction. I’d like to thank Andreas and the team for their support, advice and encouragement during the entire process.” Erik Roßmeißl, CFO and member of the executive board, WITTENSTEIN.

Kloepfel Corporate Finance has exclusively advised WITTENSTEIN and supported in structuring, negotiating and successfully executing the transaction in a competitive international M&A process.

WITTENSTEIN SE
For additional information on WITTENSTEIN: www.wittenstein.de

Orthofix Medical Inc. (NASDAQ:OFIX):
For additional information on Orthofix: www.orthofix.com

Share
0

Related posts

28. July 2021

Sale of EWK Umwelttechnik GmbH to Valmet Technology Oy


Mehr erfahren
8. March 2021

WiloSe acquires 100% of the shares of Abionik Group a portfolio company of Bid Equity


Mehr erfahren
16. November 2020

Kloepfel Corporate Finance exclusively advises the shareholders of DITTRICH + Co GmbH & Co


Mehr erfahren

Kontakt

  • Contact
  • Imprint
  • Privacy Policy

Top News

  • Kloepfel Corporate Finance exclusively advises Fire Holding GmbH on the acquisition of the ABBS Group
  • Management Buy Out (MBO)

Kontakt

Kloepfel Corporate Finance
Rundfunkplatz 2
80335 München

T: +49 892 060 541 30
M: info@kloepfel-cf.com

© 2025 Kloepfel Corporate Finance GmbH | Wordpress/Design: www.creationell.de
English
  • No translations available for this page